Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Dec;30(4):803-17.
doi: 10.1016/j.psc.2007.07.003.

Psychiatric issues in multiple sclerosis

Lydia A Chwastiak  1 , Dawn M Ehde
Affiliations
Review

Psychiatric issues in multiple sclerosis

Lydia A Chwastiak et al. Psychiatr Clin North Am. 2007 Dec.

Abstract

MDD and anxiety disorders are highly prevalent among persons who have MS and have been associated with decreased adherence to MS treatment and poorer functional status and quality of life. Effective treatment is available for MDD, but this disorder continues to be underdetected and undertreated by MS providers. Treatment with pharmacotherapy is particularly challenging in this patient population, given the somatic symptom overlap between MS and depression and the increased burden of side effects. Larger randomized, controlled trials are needed to elucidate further the effectiveness of pharmacotherapy and to identify subgroups of patients who would benefit from this type of treatment for depression. There have been few rigorous studies of the prevalence and impact of anxiety disorders, substance use disorders, or serious mental illness such as bipolar disorder or schizophrenia, in MS samples.

PubMed Disclaimer

References

    1. Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin Proc. 1997;72:871–878. - PubMed
    1. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6:91–98. - PubMed
    1. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–533. - PubMed
    1. Tsivgoulis G, Triantafyllou N, Papageorgiou C, et al. Associations of the Expanded Disability Status Scale with anxiety and depression in multiple sclerosis outpatients. Acta Neruol Scand. 2007;115:67–72. - PubMed
    1. Amato MP, Ponziani G, Rossi F, et al. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001;7:340–344. - PubMed